Reimbursement – Hymovis for Healthcare Professionals

This convenient program includes insurance benefit investigation and prior authorization support, and timely status updates.

Complete support for your office to prescribe HYMOVIS^® with confidence

Quick turnaround (2 business days or less)

Patient-specific Benefits Investigation

Prior Authorization Applications and Renewals

Appeals Assistance

Specialty Pharmacy Triage

Real-time enrollment status updates

Allows for maximized visibility and the insight necessary to track a referral’s journey throughout the fulfillment process.

Support hotline 1-866-749-2542, Option 2

Reimbursement support
Physician support services

Available Monday-Friday, 9 AM to 8 PM ET
Fax: 1-877-447-9734
For patient insurance verification, register/login to: www.fidiacomplete.com

Access necessary resources for reimbursement

Letter of Medical Necessity

HYMOVIS^® Reimbursement Guide

Fidia Complete Portal Registration Information

Fidia Complete Reimbursement Portal Login

Prior Authorization Checklist

Tips for Clean Claims Submission

Benefits Investigation Patient Form

Coding information for HYMOVIS

Overview of Reimbursement Support

Sample CMS 1450 Form for HYMOVIS

Sample CMS 1500 Form for HYMOVIS

Strategies to Appeal Denied Claims

Indication

HYMOVIS^® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

Important Safety Information

HYMOVIS^® is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer HYMOVIS^® to patients with infections or skin diseases in the area of the injection site or joint. The safety and effectiveness of the use of HYMOVIS^® have not been tested in pregnant women, nursing mothers, or children. The safety and effectiveness of the use of HYMOVIS^® in joints other than the knee, or for use concomitantly with other intra-articular (IA) injections, have not been established. The effectiveness of repeat treatment cycles of HYMOVIS^® has not been established.

Arthralgia, transient pain, or swelling may occur after the IA injection. The incidence of arthralgia in the clinical study for HYMOVIS^® was equivalent to the control group. No serious adverse events or pseudoseptic reactions were reported. Transient increases in inflammation following any IA hyaluronan injection have been reported in some patients with inflammatory joint conditions.

Please see full Prescribing Information including indications, contraindications, warnings, precautions, and adverse events.

Rx Only.

Please see Full Prescribing Information.

^aData obtained from the ANTIAGE National Registry (Italy): Associazione Nazionale por la Terapia Intra Articcolare con Guida Ecografica (ANTIAGE) - A nonprofit database of clinical data on effects of ultrasound-guided intra-articular viscosupplementation

The only 2-injection hyaluronic acid regimen for osteoarthritis knee pain

This convenient program includes insurance benefit investigation and prior authorization support, and timely status updates.

Complete support for your office to prescribe HYMOVIS® with confidence

Real-time enrollment status updates

Support hotline 1-866-749-2542, Option 2

Access necessary resources for reimbursement

References

STUDY SUMMARY: BISICCHIA S, 2016

HYMOVIS® (HYADD® 4) Versus Methylprednisolone Acetate in Symptomatic Knee Osteoarthritis: A Single-centre Single Blind Prospective Randomised Controlled Clinical Study With a 1-year Follow-up5

Study design

Objective

Study population

Intervention

Primary endpoint

STUDY SUMMARY: BENAZZO F, 2016

A Multi-centre, Open-label, Long-term Follow-up Study to Evaluate The Benefits of a New Viscoelastic Hydrogel (HYMOVIS®) in The Treatment of Knee Osteoarthritis7

Study design

Objective

Study population

Intervention

Primary endpoint

Secondary endpoints

STUDY SUMMARY: PRIANO F, 2017

Post-market retrospective study evaluating real-world use of HYMOVIS®

Early Efficacy of Intra-articular HYADD® 4 (HYMOVIS®) Injections for Symptomatic Knee Osteoarthritis6

Study objective

Study design

The only 2-injection
hyaluronic acid regimen for
osteoarthritis knee pain

Complete support for your office to prescribe HYMOVIS^® with confidence

HYMOVIS^® (HYADD^® 4) Versus Methylprednisolone Acetate in Symptomatic Knee Osteoarthritis: A Single-centre Single Blind Prospective Randomised Controlled Clinical Study With a 1-year Follow-up⁵

A Multi-centre, Open-label, Long-term Follow-up Study to Evaluate The Benefits of a New Viscoelastic Hydrogel (HYMOVIS^®) in The Treatment of Knee Osteoarthritis⁷

Post-market retrospective study evaluating real-world use of HYMOVIS^®

Early Efficacy of Intra-articular HYADD^® 4 (HYMOVIS^®) Injections for Symptomatic Knee Osteoarthritis⁶